• Phase 1b/2 trial of AsiDNATM in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant prostate cancer continues to enroll patients
    • Advancing Second Product, OX425, a pan-DDR decoy targeting multiple proteins & repair pathways towards submission of US IND in the second half of 2023
      • Preclinical update at AACR 2023 provided a comprehensive preclinical rationale for the potential use of OX425 in patients bearing HRD/HRP tumors or acquired PARPi-resistance
    • Cash position of €14.6 million as of December 31, 2022
    • Financial visibility until the 2nd quarter of 2024

     

    Paris (France), April 24, 2023 – 8:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today reported its consolidated results for the fiscal year ending December 31, 2022.

    Dr. Shefali Agarwal, Chairwoman of the Board of Directors and CEO, stated: “2022 was a pivotal year for our Company, with renewed governance. Thanks to the support of our two main and historical shareholders, Invus and Financière de la Montagne, we were able to refocus our R&D efforts to the United States. A first major step in this direction was the FDA clearance of the initial Investigational New Drug (IND) application for AsiDNATM, our first-in-class drug candidate, last June 30. Since then, we have initiated, in December 2022, a Phase 1b/2 trial for AsiDNATM in combination with Olaparib in recurrent ovarian, breast and metastatic castration-resistant prostate cancer.  At the same time, REVOCAN study, Phase 1b/2 study is ongoing, and we observed encouraging activity from the preliminary data highlighting the potential of AsiDNATM for patients with recurrent ovarian cancer who are progressing on an initial treatment with a PARP inhibitor. This study sponsored by Gustave Roussy Cancer Campus continues to enroll patients and we look forward to obtaining additional data. Last but not least, we are finalizing the preclinical development of OX425, our new compound sourced from the PlatON™ platform, in order to file an IND application in the United States in the second half of 2023.

    As the company is actively moving forward its R&D portfolio, the Company has received the necessary financial support, which will allow the extension of the Company’s runway to the second quarter of 2024.”